QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics

 QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed
                    for Clinical Research and Diagnostics

PR Newswire

MARCO ISLAND, Florida, and HILDEN, Germany, February 20, 2013

MARCO ISLAND, Florida, and HILDEN, Germany, February 20, 2013 /PRNewswire/ --

  oStreamlined and automated NGS workflow will offer many features required
    to enable routine use in clinical applications
  oBuilding on strengths in Sample & Assay Technologies to create an
    integrated NGS ecosystem with sample processing, genomic testing and
  oNew consumable products address critical workflow challenges, expanding
    QIAGEN's portfolio of "universal" solutions for use on any NGS system

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today provided new
insights into its next-generation sequencing (NGS) initiative, unveiling an
innovative sample-to-result NGS workflow designed to enable the routine use of
this breakthrough technology beyond life sciences research in areas such as
clinical research and diagnostics.

QIAGEN's NGS workflow - an ecosystem of products and services to offer
automated processes from primary sample to digital result - is being presented
to customers this week at the 14th annual Advances in Genome Biology and
Technology (AGBT) meeting in Marco Island, Florida.

"Next-generation sequencing is making a transformational impact on life
science, but challenges are limiting more widespread adoption for clinical
purposes. We are pleased with the progress of our NGS initiative to create a
complete portfolio of products and services to make this breakthrough
technology more effective, robust and scalable for areas such as clinical
research and diagnostics," said Peer M. Schatz, Chief Executive Officer of
QIAGEN. "The development of our complete sample-to-result workflow is a key
achievement in our initiative to offer a seamless integration of new NGS
platforms with high-quality reagents, molecular testing content and services."

"We are leveraging our core expertise with new and existing QIAGEN products to
develop the solutions needed for adoption of NGS technologies in new areas
beyond basic research," said Dr. Dietrich Hauffe, Senior Vice President, Life
Sciences Business Area at QIAGEN. "We are planning to begin placing NGS
workflows with selected customer groups during 2013. We expect NGS to
complement established molecular technologies, particularly real-time PCR, and
to become an important contributor to QIAGEN's leadership in Sample & Assay

The adoption of NGS in fields such as clinical research and diagnostics has
been hampered for a number of reasons, particularly workflow challenges that
become more pronounced in clinical settings due in part to the increased
number of samples being processed. Other challenges include manual sample
preparation processes, delays caused by batching samples to achieve
cost-efficient runs, and the speed and quality of data analysis.

QIAGEN's highly automated NGS workflow addresses these challenges by offering
a streamlined and automated workflow built on components that include the

  oQIAGEN's QIAcube^® for fully automated nucleic acid isolation and
    purification, as well as library preparation.
  oNew GeneRead^[^TM^] DNAseq Target Enrichment gene panels designed for NGS
    applications based on the GeneGlobe^® collection of more than 60,000 fully
    annotated molecular assays.
  oQIAcube NGS - a new QIAcube-based instrument for automated sequencing
    template preparation.
  oGeneReader^[^TM^] - a new NGS benchtop sequencer that embraces many
    diagnostic workflow features and offers a high level of flexibility,
    scalability and efficiency.
  oA dedicated QIAGEN software solution for user-friendly and automated
    result analysis.

A key element of QIAGEN's NGS workflow is GeneReader, a transformational NGS
benchtop sequencer that offers many features essential for customers in
clinical research and diagnostics to create routine laboratory processes.
Unlike competitors' existing NGS platforms, which process only one flow cell
at a time and often require sample pooling for cost-efficient runs, the
GeneReader NGS sequencer has a turntable design that enables the continuous
loading of up to 20 flow cells for independent and parallel sequencing.
Individual patient samples also can be handled cost-efficiently without the
need for indexing or bar-coding, which means processing can occur at any time,
and in any order, without delay or concerns about potential regulatory issues.

QIAGEN has exclusively licensed sequencing-by-synthesis (SBS) chemistry for
its NGS workflow, which allows for very cost-efficient runs due to a unique
combination of dark and fluorophore-labeled "terminator nucleotides." This
chemistry provides state-of-the-art sequencing accuracy with difficult DNA
motifs such as DNA homopolymers, which are known to be problematic for
competitor sequencing chemistries.

The NGS workflow development program is on track and currently in the
"verification phase" of development, with testing under way to ensure that
performance and reliability match customer expectations. A version of the NGS
workflow based on the modular QIAsymphony^® automation platform also is under
development. In addition, QIAGEN is collaborating with SAP AG on
bioinformatics efforts aimed at significantly reducing the time required for
the analysis of sequencing data through the use of the SAP HANA^® platform.

New "universal" consumable NGS products launched

QIAGEN has launched two additional "universal" NGS consumable solutions that
are compatible with current NGS instruments:

  oGeneRead DNA Library Prep Kits - enabling DNA library preparation for NGS
    up to 50% faster, with high yields from samples as small as 50 nanogram
  oGeneRead Size Selection Kit - a convenient and efficient NGS library
    preparation method

In late 2012, QIAGEN launched its NGS initiative with the introduction of four
products that simplify sample preparation and save pre-analytical time, as
well as nine cancer gene panels for targeted NGS analysis based on the
GeneGlobe portfolio of more than 60,000 annotated molecular assays. Initial
customer demand has been very strong for these products, which are "universal"
and can be used on any NGS platform.

For more information on NGS products and resources visit


QIAGEN N.V., a Netherlands holding company, is the leading global provider of
Sample & Assay Technologies that are used to transform biological materials
into valuable molecular information. Sample technologies are used to isolate
and process DNA, RNA and proteins from biological samples such as blood or
tissue. Assay technologies are then used to make these isolated biomolecules
visible and ready for interpretation. QIAGEN markets more than 500 products
around the world, selling both consumable kits and automation systems to
customers through four customer classes: Molecular Diagnostics (human
healthcare), Applied Testing (forensics, veterinary testing and food safety),
Pharma (pharmaceutical and biotechnology companies) and Academia (life
sciences research). As of December 31, 2012, QIAGEN employed approximately
4,000 people in more than 35 locations worldwide. Further information can be
found at http://www.qiagen.com/.

Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, markets, strategy or operating
results, including without limitation its expected operating results, are
forward-looking, such statements are based on current expectations and
assumptions that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks associated with
management of growth and international operations (including the effects of
currency fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer classes, the
commercial development of markets for our products inapplied testing,
personalized healthcare, clinical research,proteomics, women's
health/HPVtesting andnucleic acid-basedmolecular diagnostics; changing
relationships with customers, suppliers and strategic partners; competition;
rapid or unexpected changes in technologies; fluctuations in demand for
QIAGEN's products (including fluctuations due to general economic conditions,
the level and timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties in
successfully adapting QIAGEN's products to integrated solutions and producing
such products; the ability of QIAGEN to identify and develop new products and
to differentiate and protect our products from competitors' products; market
acceptance of QIAGEN's new products, the consummation of acquisitions, and the
integration of acquired technologies and businesses. For further information,
please refer to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission (SEC).

These products are intended for laboratory use. Not for use in diagnostic
procedures. No claim or representation is made that these products are
intended to provide information for the diagnosis, prevention, or treatment of


Public Relations:
Dr. Thomas Theuringer
Director Public Relations
Email: pr@qiagen.com


Investor Relations:
John Gilardi
Vice President Corporate Communications

Peter Vozzo
Director, Global Investor Relations
Email: ir@qiagen.com

SOURCE Qiagen N.V.
Press spacebar to pause and continue. Press esc to stop.